Rodman & Renshaw reiterated its EpiCept EPCT Market Outperform rating and $2 price target in a research report published today.
In the report, Rodman & Renshaw states, "The potential to initiate a new Phase 3 trial of Ceplene with overall survival as an endpoint creates a path forward for the drug in the US, and the FDA's recommendation of including an IL-2 monotherapy arm creates a more robust study, especially considering that the clinical profile of IL-2 monotherapy in AML remission is largely already known. Additionally, the proposed design for the new Phase 3 trial of Ceplene contains several further improvements (see Table, next page) that could bode well for improving the chances of a positive outcome."
Shares of EpiCept were trading at $0.46 at the time of posting, up 9.52% from Friday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in